Biophytis SA (BPTS): Price and Financial Metrics
BPTS Price/Volume Stats
| Current price | $0.29 | 52-week high | $4.22 |
| Prev. close | $0.33 | 52-week low | $0.27 |
| Day low | $0.28 | Volume | 182,700 |
| Day high | $0.30 | Avg. volume | 284,645 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.92 | Market Cap | 4.08M |
BPTS Stock Price Chart Interactive Chart >
Biophytis SA (BPTS) Company Bio
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.
Latest BPTS News From Around the Web
Below are the latest news stories about BIOPHYTIS SA that investors may wish to consider to help them evaluate BPTS as an investment opportunity.
Biophytis Announces Receipt of Nasdaq NoticePARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that ... |
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in BrazilPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 30,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing ... |
Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings PanelPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 27, 2023 / Biophytis SA (NASDAQCM:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing ... |
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its OperationsStart of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA)Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first, opening up the prospect ... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors! |
BPTS Price Returns
| 1-mo | -26.49% |
| 3-mo | -42.25% |
| 6-mo | -68.31% |
| 1-year | -92.29% |
| 3-year | -99.78% |
| 5-year | N/A |
| YTD | -56.76% |
| 2023 | -83.02% |
| 2022 | -92.60% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...